MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, announced on [date not specified] that it has engaged Venture Liquidity Providers (VLP) to provide market-making services. The appointment is subject to regulatory and final approvals.
Under the agreement, VLP will conduct market-making services through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies. MindBio has agreed to pay $5,000 per month over a 12-month term, which may be terminated at any time. Both parties operate at arm’s length, and VLP holds no direct or indirect interest in the company or its securities.
The engagement of VLP is intended to maintain an orderly trading market for MindBio's common shares. Market-making services can enhance liquidity and ensure that there is a continuous bid and ask price for the stock, which benefits shareholders by potentially reducing volatility and improving the ability to buy or sell shares.
MindBio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
For more information on the press release, visit https://ibn.fm/4evlA. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
